65,437 trials
Chronic Kidney Disease · Inflammation · Cardiovascular Risk
Primary: Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End…
Stroke
Primary: Recruitment — 20 Participants
Trauma Injury · Physician's Role
Primary: Under-triage — 819; 919; 417; 392 Severely injured patients — p=0.02
Breast Cancer
Primary: Change in Percentage of Total Fatty Acids for Each Polyunsaturated Fatty Acid (PUFA) Group From Start of Omega-3 Fatty Acid (O3-FA) Supplementation to 3 Months of O3-FA…
Physiologically Based Pharmacokinetic · Healthy Volunteers
Primary: AUC(0-24h) — 7373.6; 7195.7 ng·min/mL
Head and Neck Cancer
Primary: Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab — 17 Participants
Loneliness
Primary: Feasibility of Intervention — 18.0; 19.7; 16.2; 16.7 score on a scale
Healthy
Primary: Effects of Naloxone on Heart Rate (HR). — 73.3; 70.6 bpm
Head and Neck Cancer
Primary: Overall Response — 0; 1; 1; 8 Participants
Adult Diffuse Large Cell Lymphoma · Recurrent · Adult Refractory Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate Using Modified Cheson Criteria to Treatment With DPX-Survivac and Low Dose Cyclophosphamide Administered Together With Pembrolizumab in…
Lung Cancer · Liver Cancer · Breast Cancer
Primary: CBCT Image Quality - Artifact Index — 20.2; 32.9; 59.2; 17.3 HU
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05
Attention-Deficit Hyperactivity Disorder (ADHD)
Primary: Number of Participants With Improvement ≥ 40% in ADHD-RS-IV From Baseline up to 8 Weeks Treatment — 11; 9; 10 Participants
Prostate Cancer
Primary: Cardiac Safety Via Electrocardiography (EKG) — 0; 0; 0; 1 Participants
Myopia
Primary: The Statistical Correlation Between Three-year Change in Choroidal Thickness and Three-year Change in Axial Length — 0.18 mm axial length — p=<0.001